{
    "clinical_study": {
        "@rank": "116205", 
        "acronym": "GI-NET", 
        "arm_group": {
            "arm_group_label": "fosbretabulin tromethamine", 
            "arm_group_type": "Experimental", 
            "description": "Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles"
        }, 
        "brief_summary": {
            "textblock": "This protocol will investigate the safety, symptoms and biomarker response of subjects with\n      biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic\n      GI-NETs with elevated biochemical markers who have relapsed during or after receiving prior\n      standard of care therapies, including octreotide, chemotherapy or targeted therapy."
        }, 
        "brief_title": "A Phase 2 Study of Fosbretabulin in Subjects With Gastrointestinal Neuroendocrine Tumors (GI-NET) and With Elevated Biomarkers", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastrointestinal Neuroendocrine Tumors", 
        "condition_browse": {
            "mesh_term": "Neuroendocrine Tumors"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to read, understand and provide written consent to participate in the study\n\n          -  Age \u2265 18 years\n\n          -  Biopsy-proven well-differentiated, low-to-intermediate-grade GI-NET with elevated (>\n             ULN) biomarkers (serotonin, 5-hydroxyindoleacetic acid (5-HIAA), chromogranin A\n             (CgA), neurokinin A, and neuron-specific enolase (NSE))\n\n          -  Life expectancy > 12 weeks\n\n          -  Must have received or may still be receiving one or more therapies including\n             octreotide or serotonin synthesis inhibitor (SSI) or other somatostatin analogues\n\n          -  Confirmed progressive disease within 18 months of enrollment on study\n\n          -  Recovered from prior radiation therapy or surgery\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance score 0-2\n\n          -  Absolute neutrophil count (ANC) \u2265 1,500/\u00b5L (without growth factors)\n\n          -  Platelet count \u2265 100,000/\u00b5L\n\n          -  Adequate renal function as evidenced by serum creatinine\n\n             \u2264 2.0 mg/dL (177 \u00b5mol/L)\n\n          -  Adequate hepatic function: serum total bilirubin \u2264 2X greater than the upper limit of\n             normal (ULN) (\u2264 3X ULN in subjects with liver metastases), AST (Aspartate\n             aminotransferase)/ALT (Alanine aminotransferase) \u2264 2X the ULN for the local reference\n             lab (\u2264 5X the ULN for subjects with liver metastases)\n\n          -  Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide\n             imaging or other imaging modality)\n\n          -  Women of childbearing potential as well as fertile men and their partners must use an\n             effective method of birth control\n\n        Exclusion Criteria:\n\n          -  Inadequately controlled hypertension defined as BP > 150/100 mm Hg despite medication\n\n          -  Prior history of hypertensive crisis or hypertensive encephalopathy\n\n          -  Recent history (within 6 months of start of screening) of unstable angina pectoris\n             pattern, myocardial infarction (including non-Q wave MI), or NYHA (New York Heart\n             Association) Class III and IV  Congestive Heart Failure (CHF)\n\n          -  Subjects who have clinical evidence of carcinoid-induced heart disease\n\n          -  History of prior cerebrovascular accident (CVA), including transient ischemic attach\n             (TIA)\n\n          -  Known central nervous system (CNS) disease except for treated brain metastasis\n\n          -  History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic\n             sinus bradycardia (<60 bpm), heart block (excluding 1st degree block, being PR\n             interval prolongation only), congenital long QT syndrome or new ST segment elevation\n             or depression or new Q wave on ECG\n\n          -  Corrected QT interval (QTc) > 480 msec\n\n          -  Ongoing treatment with any drugs known to prolong the QTc interval, including\n             anti-arrhythmic medications (stable regimen of antidepressants of the selective\n             serotonin reuptake inhibitor (SSRI) class is allowed))\n\n          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of\n             therapeutic anticoagulation)\n\n          -  Significant vascular disease or recent peripheral arterial thrombosis\n\n          -  Known intolerance of or hypersensitivity to fosbretabulin\n\n          -  History of solid organ transplant or bone marrow transplant\n\n          -  Any other intercurrent medical condition, including mental illness or substance\n             abuse, deemed by the Investigator to be likely to interfere with a subject's ability\n             to sign informed consent, cooperate and participate in the study, or interfere with\n             the interpretation of the results\n\n          -  High grade or poorly differentiated NET\n\n          -  Pancreatic or other non-GI-NET/carcinoid\n\n          -  No elevated biomarker (>ULN) that can be followed\n\n          -  Received regional hepatic infusion therapy within 6 months of enrollment (RFA allowed\n             >6 months prior to enrollment)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132468", 
            "org_study_id": "OX4218s"
        }, 
        "intervention": {
            "arm_group_label": "fosbretabulin tromethamine", 
            "description": "60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity", 
            "intervention_name": "fosbretabulin tromethamine", 
            "intervention_type": "Drug", 
            "other_name": "fosbretabulin, combretastatin A4-phosphate, CA4P"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Combretastatin", 
                "Combretastatin A-4"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "GI NET", 
            "neuroendocrine", 
            "carcinoid"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Gastrointestinal Neuroendocrine Tumors/Carcinoid (GI-NET) With Elevated Biomarkers", 
        "overall_contact": {
            "email": "scruikshank@oxigene.com", 
            "last_name": "Susan A Cruikshank, MPA, BS", 
            "phone": "650-635-7012"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from one or more baseline biomarker values for each patient to each study visit and study end", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132468"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "OXiGENE", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "OXiGENE", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}